Using vasopressin and steroids with adrenaline for cardiac arrest treatment
VAsopressin and STeroids in Addition to Adrenaline in Cardiac Arrest - a Randomized Clinical Trial
This study is testing if adding vasopressin and steroids to standard adrenaline treatment can help improve survival rates for patients who have a cardiac arrest in the hospital.
Quick facts
| Phase | Phase 3 |
|---|---|
| Study type | Interventional |
| Enrollment | 1276 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Tiohundra AB Industry-sponsored |
| Locations | 2 sites (Gothenburg and 1 other locations) |
| Trial ID | NCT05139849 on ClinicalTrials.gov |
What this trial studies
This clinical trial investigates the effectiveness of adding vasopressin and methylprednisolone to standard adrenaline treatment in patients experiencing in-hospital cardiac arrest. It is a randomized, placebo-controlled, double-blind study involving approximately 1400 participants over a projected period of 3-4 years. Eligible patients are those who meet the criteria for adrenaline administration according to current guidelines. The trial aims to determine if this combination can improve survival rates from 9% to 14%. Informed consent will be obtained from patients or their representatives post-resuscitation.
Who should consider this trial
Good fit: Ideal candidates are hospitalized men over 18 years and women over 50 years who are experiencing in-hospital cardiac arrest.
Not a fit: Patients who are not capable of comprehending information for participation, women of childbearing potential, and those with a do not resuscitate (DNR) decision will not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly improve survival rates for patients experiencing cardiac arrest.
How similar studies have performed: Other studies have explored similar combinations of treatments, but this specific approach is novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Hospitalized men \> 18 years and hospitalized women \> 50 years. Exclusion Criteria: * Patients not capable to comprehend information to decide about participation in the study * Women considered of childbearing potential (WOCBP) i. e. premenopausal women * Patients with do not resuscitate (DNR) descision * Prior enrollment and randomization in the trial
Where this trial is running
Gothenburg and 1 other locations
- Sahlgrenska University Hospital — Gothenburg, Sweden (Recruiting)
- Tiohundra — Norrtälje, Sweden (Recruiting)
Study contacts
- Principal investigator: Sune Forsberg, MD, PhD — Tiohundra AB
- Study coordinator: Sune Forsberg, MD, PhD
- Email: sune.forsberg@tiohundra.se
- Phone: +46722037953
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.